Rx Combo Slowed Multiple Myeloma
When it comes to treating multiple myeloma, three medications may be better than two.
Blood Cancer Rx Trial Halted
The purpose of clinical trials is to study the safety and effectiveness of a medication. Sometimes, clinical trials involving humans find that a medication does not work and the study is stopped. This just happened in a trial looking at a blood cancer medication.
Personalizing Blood Cancer Treatment
Huge advances have been made in the understanding of multiple myeloma. There are a variety of approaches for treating this blood cancer. The trick is to provide what’s best for the individual patient.
New Rx for Advanced Multiple Myeloma
Multiple myeloma is a blood cancer that affects nearly 22,000 Americans every year. It develops in mostly older people when plasma cells in the bone marrow grow out of control.
Stronger Blood Cancer Drug Appears Successful
Part of the treatment for especially severe cancers of the blood is to destroy all the cells in the bone marrow that are responsible for making both the good and bad parts of the blood with radiation therapy.
Cancer Rx Linked to Second Cancers
Health Canada, the Canadian version of the U.S. Food & Drug Administration (FDA), has issued an alert regarding the medication REVLIMID ( lenalidomide ) that's used to treat multiple myeloma .
Keys to Unlocking Multiple Myeloma Resistance
People living with the blood cancer multiple myeloma typically take two drugs in combination. The problem is these drugs don't work with every person and tend to fade in effectiveness over time.
New Hope for Multiple Myeloma Patients
While there is no cure for multiple myeloma, a form of blood cancer, new therapy offers hope for keeping the disease from progressing. When used as a maintenance or ongoing therapy, Revlimid (lenalidomide) delays the progression of multiple myeloma and improves overall survival of newly diagnosed patients who have had a stem-cell transplant.